244 related articles for article (PubMed ID: 35502786)
1. Coverage of New Drugs in Medicare Part D.
Naci H; Kyriopoulos I; Feldman WB; Hwang TJ; Kesselheim AS; Chandra A
Milbank Q; 2022 Jun; 100(2):562-588. PubMed ID: 35502786
[TBL] [Abstract][Full Text] [Related]
2. Coverage of Novel Therapeutic Agents by Medicare Prescription Drug Plans Following FDA Approval.
Shaw DL; Dhruva SS; Ross JS
J Manag Care Spec Pharm; 2018 Dec; 24(12):1230-1238. PubMed ID: 30479199
[TBL] [Abstract][Full Text] [Related]
3. Placement of selected new FDA-approved drugs in Medicare Part D formularies, 2009-2013.
Stuart BC; Tom SE; Choi M; Johnson A; Sun K; Qato D; Obi EN; Zacker C; Park Y; Arcona S
Am J Manag Care; 2018 Jun; 24(6):e175-e182. PubMed ID: 29939507
[TBL] [Abstract][Full Text] [Related]
4. Biosimilar formulary placement in Medicare Part D prescription drug plans: A case study of infliximab.
Socal MP; Ezebilo I; Bai G; Anderson GF
Am J Health Syst Pharm; 2021 Jan; 78(3):216-221. PubMed ID: 33289035
[TBL] [Abstract][Full Text] [Related]
5. Association of Formulary Exclusions and Restrictions for Opioid Alternatives With Opioid Prescribing Among Medicare Beneficiaries.
Rao T; Kiptanui Z; Dowell P; Triebwasser C; Alexander GC; Harris I
JAMA Netw Open; 2020 Mar; 3(3):e200274. PubMed ID: 32119095
[TBL] [Abstract][Full Text] [Related]
6. Medicare Part D Plans Greatly Increased Utilization Restrictions On Prescription Drugs, 2011-20.
Joyce G; Blaylock B; Chen J; Van Nuys K
Health Aff (Millwood); 2024 Mar; 43(3):391-397. PubMed ID: 38437610
[TBL] [Abstract][Full Text] [Related]
7. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
8. Medicare Part D Plans Rarely Cover Brand-Name Drugs When Generics Are Available.
Dusetzina SB; Cubanski J; Nshuti L; True S; Hoadley J; Roberts D; Neuman T
Health Aff (Millwood); 2020 Aug; 39(8):1326-1333. PubMed ID: 32744944
[TBL] [Abstract][Full Text] [Related]
9. Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D.
Dusetzina SB; Sarpatwari A; Carrier MA; Hansen RA; Keating NL; Huskamp HA
JAMA Intern Med; 2021 Dec; 181(12):1605-1611. PubMed ID: 34661600
[TBL] [Abstract][Full Text] [Related]
10. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
11. Medicare Prescription Drug Plan Formulary Restrictions After Postmarket FDA Black Box Warnings.
Solotke MT; Ross JS; Shah ND; Karaca-Mandic P; Dhruva SS
J Manag Care Spec Pharm; 2019 Nov; 25(11):1201-1217. PubMed ID: 31663461
[TBL] [Abstract][Full Text] [Related]
12. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
13. Medicare Part D roulette: potential implications of random assignment and plan restrictions.
Patel RA; Walberg MP; Woelfel JA; Amaral MM; Varu P
Medicare Medicaid Res Rev; 2013; 3(2):. PubMed ID: 24753963
[TBL] [Abstract][Full Text] [Related]
14. Patients' access to 2018 FDA-approved drugs 1 year post approval.
Panzer AD; Margaretos NM; Bridger N; Osani MC; Lai RC; Chambers JD
Am J Manag Care; 2022 Apr; 28(4):e153-e156. PubMed ID: 35420754
[TBL] [Abstract][Full Text] [Related]
15. Prescription Drug Coverage for Treatment of Low Back Pain Among US Medicaid, Medicare Advantage, and Commercial Insurers.
Lin DH; Jones CM; Compton WM; Heyward J; Losby JL; Murimi IB; Baldwin GT; Ballreich JM; Thomas DA; Bicket M; Porter L; Tierce JC; Alexander GC
JAMA Netw Open; 2018 Jun; 1(2):e180235. PubMed ID: 30646077
[TBL] [Abstract][Full Text] [Related]
16. Medicare Part D and nursing home residents.
Stevenson DG; Huskamp HA; Keating NL; Newhouse JP
J Am Geriatr Soc; 2007 Jul; 55(7):1115-25. PubMed ID: 17608889
[TBL] [Abstract][Full Text] [Related]
17. Medicare Part D formulary coverage since program inception: are beneficiaries choosing wisely?
Jackson EA; Axelsen KJ
Am J Manag Care; 2008 Nov; 14(11 Suppl):SP29-35. PubMed ID: 18991478
[TBL] [Abstract][Full Text] [Related]
18. Prostaglandin Coverage and Costs to Medicare and Medicare Beneficiaries, 2009-2017.
Bartlett VL; Liu P; Dhruva SS; Shah ND; Bollinger KE; Ross JS
J Manag Care Spec Pharm; 2020 Apr; 26(4):562-567. PubMed ID: 32223594
[TBL] [Abstract][Full Text] [Related]
19. Coverage for hepatitis C drugs in Medicare Part D.
Jung JK; Feldman R; Cheong C; Du P; Leslie D
Am J Manag Care; 2016 May; 22(6 Spec No.):SP220-6. PubMed ID: 27266952
[TBL] [Abstract][Full Text] [Related]
20. Identifying widely covered drugs and drug coverage variation among Medicare part D formularies.
Tseng CW; Mangione CM; Brook RH; Keeler E; Dudley RA
JAMA; 2007 Jun; 297(23):2596-602. PubMed ID: 17579228
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
